The experimental and clinical evidence linking YAP or TAZ activation to cancer development and progression suggests that TEAD inhibitors could be effective treatments for several different cancer types, and preclinical studies using TEAD inhibitors have yielded promising results [69,70,71,72]. Here, YAP1 is linked to cancer.